缓解化的胃肠道副作用:对Bletilla条纹多糖酸微针贴片的研究
Cong Wang1, Wenting Liu1, Yong Huang1
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine/Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education)/Guizhou Provincial Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Guizhou Medical University, Gui'an New District, Guizhou 561113, China; School of Pharmacy, Guizhou Medical University, Gui'an New District, Guizhou 561113, China.
新的微针可以通过皮肤有效地输送化酸盐 (RIS),为骨质疏松症提供更好的治疗方法. 这种通过皮肤的方法避免了与口服药物相关的胃肠道副作用.
科学领域:
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
- 纳米技术纳米技术
背景情况:
- 口服酸瑞塞德 (RIS) 是绝经后骨质疏松症的关键治疗方法.
- 由于潜在的胃肠道副作用和患者遵守问题,口服给药带来了挑战,特别是对于那些经历疲劳或骨疼痛的人来说.
研究的目的:
- 开发新的Bletilla条纹多糖化微针 (RIS-BMNs) 用于通过皮肤输送瑞酸盐.
- 评估RIS-BMNs的疗效和安全性,作为骨质疏松症治疗口服RIS的替代品.
主要方法:
- 用RIS装载的Bletilla条纹多糖微针 (RIS-BMN) 的制造.
- 采用弗朗茨扩散细胞进行的体外透皮吸收研究.
- 试验室细胞活力和迁移测定用于伤口愈合.
- 在骨质疏松症大鼠的体内研究使用微型CT成像,H&E染色和生物化学标记物的分析.
主要成果:
- 与RIS溶液和贴片相比,RIS-BMNs在体外通过皮肤吸收显著更高.
- RIS-BMNs表现出最小的和短暂的皮肤刺激.
- 在体外和体外研究表明,RIS-BMNs促进细胞增殖,伤口愈合,并改善骨质疏松症大鼠的骨结构.
- 生物化学分析证实与口服RIS具有相似的抗骨质疏松作用,没有胃肠道毒性.
结论:
- 布莱蒂拉 (Bletilla) 条纹多糖化微针提供了一个有效和安全的通过皮肤传递的瑞酸盐的系统.
- 这种新的透皮方法为治疗绝经后骨质疏松症提供了一个有希望的替代方案,通过减轻胃肠道副作用,有可能改善患者的坚持治疗.
更多相关视频
03:56Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
Published on: April 26, 2024
07:42Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids
Published on: March 1, 2024
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
